Corgenix Medical Corp. has successfully completed the feasibility stage for a new, high-speed automated test format for its AspirinWorks Test, developed in collaboration with Randox Laboratories. The new format was created to make it faster and easier to perform the AspirinWorks Test at clinical labs and hospitals.

“We’ve taken another critical step forward in expanding the potential market for the AspirinWorks Test,” said Douglass Simpson, Corgenix president and chief executive. “The next step in this process will be the launch of the new fully automated immunoturbidimetric (IT) format, making it easier and faster to process large volumes of this important cardiovascular test.”

Once completed and approved by the FDA, the new IT assay will be compatible with automated chemistry analyzers. The assay will be manufactured at Randox Laboratories in the UK, and the two companies will share global distribution rights.